<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1707245595
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACCEPT 500MG F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MYCOPHENOLATE MOFETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        194.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Immunosuppressants.<br />Accept is used to prevent your body rejecting a transplanted kidney,<br />heart or liver. Accept is used together with other medicines known as<br />Cyclosporine and corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Accept<br />&bull; if you are allergic to Mycophenolate Mofetil, Mycophenolic Acid or<br />any of the other ingredients of this medicine (listed in section 6)<br />&bull; if you are breastfeeding<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking Accept.<br />You should inform your doctor immediately<br />&bull; if you experience any evidence of infection (e.g. fever, sore throat),<br />unexpected bruising and/or bleeding<br />&bull; if you have or ever have had any problems with your digestive<br />system, e.g. stomach ulcers<br />&bull; if you are planning to become pregnant, or if you become pregnant<br />while taking Accept<br />If any of the above apply to you (or you are not sure), talk to your<br />doctor straightaway before taking Accept.</p><p>The effect of sunlight<br />Mycophenolate Mofetil reduces your body&rsquo;s defences. As a result,<br />there is an increased risk of skin cancer. You can limit the amount of<br />sunlight and UV light you get by:<br />&bull; wearing protective clothing which also covers your head, neck,<br />arms and legs<br />&bull; using a sunscreen with a high protection factor<br />Other medicines and Accept<br />Tell your doctor or pharmacist if you are taking, have recently taken<br />or might take any other medicines. This includes medicines obtained<br />without a prescription, including herbal medicines.<br />This is extremely important because Accept can affect the way some<br />other medicines work. Also other medicines can affect the way<br />Accept works.<br />In particular, tell your doctor or pharmacist if you are taking any of<br />the following medicines before you start taking Accept:<br />&bull; Azathioprine or other medicines which suppress your immune<br />system (given after a transplant operation)<br />&bull; Cholestyramine (used to treat high cholesterol)<br />&bull; Rifampicin (used to prevent and treat infections such as tuberculosis<br />or TB)<br />&bull; Antacids, or Proton Pump Inhibitors (used for acid problems in your<br />stomach such as indigestion)<br />&bull; Phosphate binders (used by people with chronic kidney failure to<br />reduce how much phosphate gets absorbed into their blood )</p><p>Vaccines<br />If you need to have a vaccine (a live vaccine) while taking Accept,<br />talk to your doctor or pharmacist first. Your doctor will have to advise<br />you on what vaccines you can have.<br />Interactions with food and drink<br />Taking food and drink has no influence on your treatment with Accept.<br />Pregnancy, Breastfeeding and Fertility<br />If you are pregnant, do not take Accept. This is because<br />Mycophenolate Mofetil may cause miscarriage or damage to your<br />unborn baby (affecting development of ears for example).<br />&bull; In certain situations, you and your doctor may decide that the<br />benefits of taking Accept for your health are more important than<br />the possible risks to your unborn baby.<br />&bull; If you plan to become pregnant, talk to your doctor first. Your<br />doctor will talk to you about other medicines you can take to<br />prevent rejection of your transplanted organ.<br />&bull; If you become pregnant while taking Accept, do not stop taking<br />it, but tell your doctor about your pregnancy as soon as possible.<br />If you are able to become pregnant, you must have a pregnancy test<br />before you start Accept. You can only start this medicine if the test is<br />negative.</p><p>You are a woman who is not capable of becoming pregnant if any of<br />the following applies to you:<br />&bull; You are post-menopausal, i.e. at least 50 years old and your last<br />period was more than a year ago (if your periods have stopped<br />because you have had treatment for cancer, then there is still a<br />chance you could become pregnant).<br />&bull; Your fallopian tubes and both ovaries have been removed (bilateral<br />salpingo-oophorectomy).<br />&bull; Your womb (uterus) has been surgically removed (hysterectomy).<br />&bull; You have premature failure of the ovaries, confirmed by a specialist<br />gynaecologist.<br />&bull; You have been diagnosed with one of the following rare conditions<br />that some patients are born with that make pregnancy impossible:<br />the XY genotype, Turner&rsquo;s syndrome or uterine agenesis.<br />&bull; You are a child/teenager who has not started having periods, and<br />cannot become pregnant.</p><p>Contraception<br />You must always use an effective method of contraception with<br />Accept. This includes:<br />&bull; before you start taking Accept<br />&bull; during your entire treatment with Accept<br />&bull; for 6 weeks after you stop taking Accept<br />Talk to your doctor about the most suitable contraception for you.<br />This will depend on your individual situation.<br />Breastfeeding<br />Do not take Accept if you are breastfeeding. This is because small<br />amounts of the medicine can pass into the mother&rsquo;s milk.<br />Driving and using machines<br />Accept have not been shown to impair your ability to drive or operate<br />machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Accept exactly as your doctor has told you. You should<br />check with your doctor or pharmacist if you are not sure.<br />How much to take<br />The amount you take depends on the type of transplant you have had.<br />The usual doses are shown below. Treatment will continue for as long<br />as you need to prevent you from rejecting your transplanted organ.<br />Kidney transplant<br />Adults<br />&bull; The first dose is given within 3 days of the transplant operation.<br />&bull; The daily dose is 4 tablets (2g of the active substance) taken as 2<br />separate doses.<br />&bull; Take 2 tablets in the morning and then 2 tablets in the evening.<br />Children (aged 2 to 18 years)<br />&bull; The dose given will vary depending on the size of the child.<br />&bull; Your doctor will decide the most appropriate dose based on the child&rsquo;s<br />height and weight (body surface area &ndash;measured as square metres or<br />&ldquo;m2&rdquo;). The recommended dose is 600mg/m2 taken twice a day.</p><p>Heart transplant<br />Adults<br />&bull; The first dose is given within 5 days of the transplant operation.<br />&bull; The daily dose is 6 tablets (3g of the active substance) taken as 2<br />separate doses.<br />&bull; Take 3 tablets in the morning and then 3 tablets in the evening.<br />Children<br />&bull; There is no information for the use of Mycophenolate Mofetil in<br />children with a heart transplant.<br />Liver transplant<br />Adults<br />&bull; The first dose of oral Accept will be given to you at least 4 days<br />after the transplant operation and when you are able to swallow oral<br />medicines.<br />&bull; The daily dose is 6 tablets (3g of the active substance) taken as 2<br />separate doses.<br />&bull; Take 3 tablets in the morning and then 3 tablets in the evening.<br />Children<br />&bull; There is no information for the use of Mycophenolate Mofetil in<br />children with a liver transplant.<br />Method and route of administration<br />Swallow your tablets whole with a glass of water. Do not break or<br />crush them.<br />Treatment will continue for as long as you need immunosuppression<br />to prevent you rejecting your transplanted organ.</p><p>If you take more Accept than you should<br />If you take more Accept than you have been told to take, or if someone<br />else accidentally takes this medicine, immediately see a doctor or go to<br />a hospital straightaway. Take the medicine pack with you.<br />If you forget to take Accept<br />If you forget to take your medicine at any time, take it as soon as you<br />remember, then continue to take it at the usual times. Do not take a<br />double dose to make up for a missed dose.<br />If you stop taking Accept<br />Stopping your treatment with Accept may increase the chance of<br />rejection of your transplanted organ. Do not stop taking your medicine<br />unless your doctor tells you to.<br />If you have further questions on the use of this medicine, ask your<br />doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Talk to a doctor straightaway if you notice any of the following<br />serious side effects as you may need urgent medical treatment:<br />&bull; you have a sign of infection such as a fever or sore throat<br />&bull; you have any unexpected bruising or bleeding<br />&bull; you have a rash, swelling of your face, lips, tongue or throat, with<br />difficulty breathing - you may be having a serious allergic reaction<br />to the medicine (such as anaphylaxis, angioeodema)<br />Other possible side effects<br />Very common (may affect more than 1 in 10 people)<br />Digestive system and mouth problems<br />&bull; feeling sick (nausea)<br />&bull; vomiting<br />Blood and lymphatic system disorders<br />&bull; fewer white cells or red cells in your blood<br />Infections and infestations<br />&bull; stomach and gut infections<br />&bull; urinary system infections<br />&bull; mouth infections</p><p>Common (may affect up to 1 in 10 people)<br />Infections and infestations<br />&bull; lung infections<br />&bull; skin infections<br />Lymph and skin cancer<br />&bull; cancer of the lymphoid tissues and skin<br />General disorders<br />&bull; fever, feeling very tired, difficulty sleeping<br />&bull; pains (such as stomach, chest, joint or muscle, pain on passing urine)<br />&bull; headache, flu symptoms and swelling<br />Skin problems<br />&bull; acne, cold sores, shingles, skin growth, hair loss, rash, itching</p><p>Urinary problems<br />&bull; kidney problems or the urgent need to pass water (urine)<br />Digestive system and mouth problems<br />&bull; swelling of the gums and mouth ulcers<br />&bull; inflammation of the pancreas, colon or stomach<br />&bull; gut problems including bleeding, liver problems<br />&bull; constipation, indigestion, loss of appetite, flatulence, diarrhoea<br />Nervous system problems<br />&bull; feeling dizzy, drowsy or numb<br />&bull; tremor, muscle spasms, convulsions<br />&bull; feeling anxious or depressed, changes in your mood or thoughts<br />Heart and blood vessel problems<br />&bull; change in blood pressure, unusual heartbeat, widening of blood vessels<br />Lung problems<br />&bull; pneumonia, bronchitis<br />&bull; shortness of breath, cough<br />&bull; fluid on the lungs or inside the chest<br />&bull; sinus problems<br />Other problems<br />&bull; weight loss, gout, high blood sugar</p><p>Not known (frequency cannot be estimated from the available data)<br />Infections and infestations<br />&bull; brain infections<br />Your doctor will do regular blood tests to check for any changes in:<br />&bull; the number of your blood cells<br />&bull; the amount in your blood of sugar, fat or cholesterol<br />Children may be more likely than adults to have some side effects.<br />These include diarrhoea, infections, fewer white cells and fewer red<br />cells in the blood.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.<br />Do not use this medicine after the expiry date which is stated on the<br />pack. The expiry date refers to the last day of that month.<br />Do not use Accept if you notice any visible signs of deterioration.<br />Medicines should not be disposed of via wastewater or household<br />waste. Ask your pharmacist how to dispose of medicines no longer<br />required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Mycophenolate Mofetil.<br />Each film-coated tablet contains 500mg of Mycophenolate Mofetil.<br />The other ingredients are:<br />Core tablet: Cellulose microcrystalline, povidone,<br />hydroxypropylcellulose, croscarmellose sodium, talc, magnesium stearate.<br />Tablet coating: Hypromellose 6 cps, titanium dioxide (E171),<br />macrogol 400, iron oxide red (E172), indigo carmine aluminium lake<br />(E132), iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Accept 500mg Tablets are purple colored, capsule shaped, biconvex,
film-coated tablets debossed “AHI” on one side and “500” on other side.
Accept 500mg Tablets are packed in blisters and are available in
different pack sizes (50 or 150 tablets per pack)
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Market Authorization Holder ( MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF,<br />United Kingdom.<br />Tel: +44 208 863 1427<br />Fax: +44 208 863 1426<br />E-mail: mena-info@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 10/2014,
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>مثبطات مناعة.<br />يُستخدَم أكسبت لمنع الجسم من رفض الأعضاء المزروعة كالكلية أو القلب أو الكبد،<br />ويُستخدَم أكسبت مع أدوية أخرى مثل سيكلوسبورين وكورتيكوستيرويد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم تناول أكسبت<br />&bull; إذا كنت تعاني من حساسية لمايكوفينوليت موفيتيل أو حمض المياكوفينولك أو أي<br />( مكونات أخرى من مكونات هذا الدواء (المذكورة في القسم رقم ٦<br />&bull; في حالة الرضاعة الطبيعية</p><p>التحذيرات والاحتياطات<br />استشِر طبيبك أو الصيدلي أو الممرضة قبل تناول أكسبت.<br />يجب إبلاغ طبيبك على الفور<br />&bull; إذا كنت تعاني من ظهور أي عرض من أعراض العدوى (مثل الحمى أو التهاب الحلق)<br />و/أو ظهور أي كدمات و/أو نزيف غير متوقعين<br />&bull; في حال وجود أي مشكلات حالية أو سابقة تتعلق بالجهاز الهضمي، مثل قرحة المعدة<br />&bull; في حال التخطيط للحمل، أو في حال الحمل أثناء تناول أكسبت<br />في حال انطباق أي من الحالات السابقة عليك (أو في حال عدم تأكدك)، تحدث إلى طبيبك<br />على الفور قبل تناول أكسبت.</p><p>تأثير أشعة الشمس<br />يقلل المايكوفينوليت موفيتيل من قدرة المناعة في جسمك. ونتيجة لذلك، يزداد خطر<br />الإصابة بسرطان الجلد. ولذا يجب أن تحدّ من تعرّضك لأشعّة الشمس والأشعّة ما فوق<br />البنفسجيّة من خلال:<br />&bull; ارتداء ملابس واقية تغطي رأسك ورقبتك وذراعيك ورجليك<br />&bull; استخدام كريم واقٍ من الشمس ذات درجة حماية مرتفعة.<br />الأدوية الأخرى وأكسبت<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو قد تتناول<br />لاحقًا أي أدوية أخرى، بما في ذلك الأدوية التي تصرف دون الحاجة إلى وصفة طبية.<br />يشمل ذلك الأدوية التي تصرف دون الحاجة إلى وصفة طبية والأدوية العشبية. يرجع<br />السبب في ذلك إلى قدرة أكسبت على التأثير في آلية عمل بعض الأدوية الأخرى، كما قد<br />تؤثر بعض الأدوية الأخرى في آلية عمله أيضًا.</p><p>وبشكل خاص، يجب إخبار الطبيب المعالج أو الصيدلي إذا كنت تتناول أيًّا من الأدوية<br />التالية قبل بدء استخدام أكسبت:<br />&bull; أزاثيوبرين أو غيرها من الأدوية المثبطة للمناعة (يتم تناولها بعد عمليات زراعة<br />الأعضاء)<br />&bull; كوليستيرامين (يُستخدم لعلاج نسبة الكوليسترول المرتفعة)<br />(TB &bull; ريفامبيسين (يُستخدم لمنع وعلاج العدوى مثل السل أو<br />&bull; مضادات الحموضة أو مثبطات مضخة البروتون (المستخدمة لعلاج مشكلات الأحماض<br />في المعدة مثل عسر الهضم)<br />&bull; الأدوية التي تُحِد من امتصاص الفوسفات (التي يستخدمها الأفراد الذين يعانون من فشل<br />كلوي مزمن لتقليل كمية الفوسفات التي يتم امتصاصها في الدم)</p><p>اللقاحات<br />تحدث إلى الطبيب أو الصيدلي أولًا عند الحاجة لتناول لقاح (لقاح حي) أثناء تناول أكسبت.<br />سينصحك طبيبك باللقاحات التي يمكنك أخذها.<br />تفاعل أكسبت مع الطعام والشراب<br />لا يؤثر تناول الطعام والشراب في العلاج باستخدام أكسبت.<br />الحمل والرضاعة والخصوبة<br />يجب عدم تناول أقراص أكسبت أثناء الحمل. ذلك لأن مايكوفينوليت موفيتيل قد يتسبب في<br />إجهاض الحمل أو قد يضر بالجنين (فهو يؤثر في نمو الأذنين على سبيل المثال).<br />&bull; في بعض الحالات، يمكن أن تقرري أنتِ وطبيبك أن فوائد تناول أكسبت لصحتك أهم من<br />المخاطر المحتملة، التي قد تؤثر في الجنين.<br />&bull; إذا كنتِ تخططين للحمل، فاستشيري الطبيب أولًا. وسيخبركِ بالأدوية الأخرى التي<br />يمكنك تناولها لمنع جسمك من رفض العضو المزروع.<br />&bull; في حال حدوث حمل أثناء تناول أكسبت، لا تتوقفي عن تناول الدواء، ولكن يجب إبلاغ<br />الطبيب بحملك في أسرع وقت ممكن.</p><p>في حال وجود إمكانية لحدوث حمل، يجب إجراء اختبار حمل قبل بدء تناول أكسبت.<br />ويمكنكِ البدء في تناول الدواء فقط إذا كانت نتيجة الاختبار سلبية.<br />لا يمكن أن تصبح المرأة حاملًا في الحالات التالية:<br />&bull; سيدة في مرحلة ما بعد انقطاع الطمث، أي تبلغ على الأقل ٥۰ عامًا وكانت آخر دورة<br />شهرية لها منذ أكثر من عام (في حال توقف الدورات الشهرية بسبب تناول علاج<br />للسرطان، فلا تزال هناك فرصة للحمل).<br />&bull; إزالة قناتي فالوب والمبيضين (الخضوع لعملية استئصال ثنائية البوق والمبيضين).<br />&bull; إزالة الرحم جراحيًّا (استئصال الرحم).<br />&bull; في حال الإصابة بفشل مبكر في المبيضين، وتأكيد طبيب أمراض نساء متخصص على<br />ذلك.<br />&bull; تشخيص الإصابة بأي من الحالات التالية التي تولد بها بعض الإناث وتجعل الحمل<br />أو متلازمة تيرنر أو عدم خلق الرحم. (XY) مستحيلًا: نمط وراثي ذكري<br />&bull; طفلة أو مراهقة لم تبدأ دورتها الشهرية بعد ولا يمكن أن تصبح حاملًا.</p><p>موانع الحمل<br />يجب دائماً استخدام طريقة فعَّالة لمنع الحمل أثناء تناول أكسبت. ويشمل ذلك:<br />&bull; فترة ما قبل بدء تناول أكسبت<br />&bull; أثناء فترة تناول أكسبت بأكملها<br />&bull; لمدة ٦ أسابيع بعد التوقف عن تناول أكسبت<br />استشيري الطبيب بشأن أكثر وسيلة لمنع الحمل تكون ملائمة لكِ. ويتوقف هذا على ظروف<br />كل حالة، كلٌّ على حدة.</p><p>الرضاعة الطبيعية<br />يجب عدم تناول أكسبت في حال الرضاعة الطبيعية، فقد تصل كميات صغيرة من الدواء<br />إلى حليب الأم.<br />القيادة وتشغيل الآلات<br />ليس لأكسبت تأثيرات عكسية في القدرة على قيادة السيارة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب الحرص دائمًا على الالتزام بالطريقة التي يحددها الطبيب لتناول أكسبت، ويجب<br />مراجعة الطبيب أو الصيدلي في حال عدم التأكد من طريقة تناول الدواء.<br />الجرعة التي يجب تناولها<br />تتوقف الكمية التي يجب تناولها على نوع عملية الزرع التي يخضع لها. وفيما يلي توضيح<br />للجرعات المعتادة. سيستمر العلاج طوال المدة اللازمة لمنع جسمك من رفض العضو<br />المزروع.</p><p>زراعة الكلى<br />البالغون<br />&bull; يتم تناول الجرعة الأولى خلال ۳ أيام من عملية الزراعة.<br />&bull; تبلغ الجرعة اليومية ٤ أقراص ( ۲ جم من الدواء) يتم تناولها على جرعتين منفصلتين.<br />&bull; تناول قرصين في الصباح ثم قرصين في المساء.<br />الأطفال (من سنتين وحتى ۱۸ سنة)<br />&bull; تختلف الجرعة حسب وزن الطفل.<br />&bull; سيقرر الطبيب الجرعة المناسبة حسب طول الطفل ووزنه (مساحة سطح الجسم &ndash;<br />تُقاس بالمتر المربع أو &quot;م ۲&quot;). والجرعة الموصي بها هي ٦۰۰ مليجرام/ م ۲ مرتان يوميًّا.<br />زراعة القلب<br />البالغون<br />&bull; يتم تناول الجرعة الأولى خلال ٥ أيام من عملية الزراعة.<br />&bull; تبلغ الجرعة اليومية ٦ أقراص ( ۳ جم من الدواء) يتم تناولها على جرعتين منفصلتين.<br />&bull; تناول ۳ أقراص في الصباح ثم ۳ أقراص في المساء.<br />الأطفال<br />&bull; لا تتوفر معلومات حول استخدام مايكوفينوليت موفيتيل مع الأطفال الذين يخضعون<br />لعملية زراعة قلب.</p><p>زراعة الكبد<br />البالغون<br />&bull; تُعطَى الجرعة الأولى من أكسبت الذي يتم تناوله عن طريق الفم بعد ٤ أيام على الأقل<br />من إجراء عملية الزراعة وعند القدرة على بلع الأدوية التي يتم تناولها عن طريق الفم.<br />&bull; تبلغ الجرعة اليومية ٦ أقراص ( ۳ جم من الدواء) يتم تناولها على جرعتين منفصلتين.<br />&bull; تناول ۳ أقراص في الصباح ثم ۳ أقراص في المساء.<br />الأطفال<br />&bull; لا تتوفر معلومات حول استخدام مايكوفينوليت موفيتيل مع الأطفال الذين يخضعون<br />لعملية زراعة كبد.</p><p>طُرُق الاستعمال<br />عن طريق الفم.<br />ابتلع الأقراص كاملة مع كوب ماء. يجب عدم كسر الأقراص أو طحنها.<br />سيستمر العلاج طوال المدة اللازمة لتثبيط الجهاز المناعي لمنع الجسم من رفض العضو<br />المزروع.</p><p>في حال تناول جرعة أكبر من أكسبت<br />في حال تناول أكسبت بجرعة أكبر من تلك الموصوفة لك، أو إذا تناول أي شخص آخر<br />هذا الدواء عن طريق الخطأ، فيجب إبلاغ الطبيب أو الانتقال إلى المستشفى فورًا.<br />واحرص على أخذ عبوة الدواء معك.<br />في حال نسيان تناول أكسبت<br />في حال نسيان تناول الدواء في أي وقت، تناوله عندما تتذكر، ثم استمر في تناوله في<br />الأوقات المعتادة. لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.<br />في حال التوقف عن تناول أكسبت<br />قد يؤدي التوقف عن تناول أكسبت إلى زيادة فرصة رفض الجسم للعضو المزروع.<br />لا تتوقف عن تناول الدواء ما لم يطلب منك الطبيب ذلك.<br />استشر الطبيب أو الصيدلي أو الممرضة إذا كان لديك أسئلة أخرى حول استخدام هذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، فهذا الدواء يمكن أن يتسبب في وجود آثار جانبية، على<br />الرغم من أنها لا تحدث للجميع.<br />أبلِغ طبيبك على الفور إذا لاحظت وجود أي آثار جانبية خطيرة مما يلي، فقد تحتاج إلى<br />علاج طبي فوري:<br />&bull; ظهور عَرَض من أعراض الإصابة بعدوى مثل الحمى أو التهاب الحلق<br />&bull; ظهور أي كدمات أو نزيف غير متوقعين<br />&bull; ظهور طفح جلدي أو تورم بالوجه أو الشفتين أو اللسان أو الحلق مع صعوبة في التنفس،<br />فربما تكون من الذين يعانون من رد فعل تحسسي خطير للدواء (مثل فرط الحساسية أو<br />الوذمة الوعائية)<br />الآثار الجانبية الأخرى المحتملة<br />الآثار الشائعة جدًّا (قد تؤثر في شخص واحد أو أكثر من بين ۱۰ أشخاص)<br />الجهاز الهضمي ومشاكل في الفم مثل:<br />&bull; الشعور بالرغبة في القيء (الغثيان)<br />&bull; القيء</p><p>اضطرابات الدم والجهاز اللمفاوي<br />&bull; انخفاض عدد كرات الدم البيضاء أو الحمراء في الدم<br />العدوى وعدوى الطفيليات<br />&bull; التهاب المعدة والأمعاء<br />&bull; التهاب الجهاز البولي<br />&bull; التهاب الفم<br />الآثار الشائعة (قد تؤثر في شخص واحد من بين ۱۰ أشخاص)<br />العدوى وعدوى الطفيليات<br />&bull; عدوى الرئة<br />&bull; عدوى الجلد<br />سرطان الجلد والغدد اللمفاوية<br />&bull; السرطان الذي يصيب الأنسجة اللمفاوية والجلد<br />الاضطرابات العامة<br />&bull; الحمى والشعور بالإرهاق وصعوبة النوم<br />&bull; الشعور بآلام (مثل آلام المعدة والصدر والمفاصل أو العضلات والألم أثناء التبول)<br />&bull; الصداع وأعراض الأنفلونزا والتورم<br />مشاكل في الجلد<br />&bull;حب الشباب وقرحة الزكام والقوباء المنطقية ونمو الجلد وفقدان الشعر والطفح الجلدي و<br />الحكة<br />مشاكل في التبول<br />&bull; مشاكل في الكلى أو الحاجة الملحة للتبول</p><p>مشاكل في الجهاز الهضمي والفم<br />&bull; تورم اللثة وقُرَح الفم<br />&bull; التهاب البنكرياس أو القولون أو المعدة<br />&bull; مشاكل في الأمعاء، والتي تتضمن النزيف، ومشاكل في الكبد<br />&bull; الإمساك وعسر الهضم وفقدان الشهية والانتفاخ والإسهال<br />مشاكل في الجهاز العصبي<br />&bull; الشعور بالدوار أو النعاس أو التنميل<br />&bull; الرعاش وتشنجات العضلات والاختلاجات<br />&bull; الشعور بالتوتر أو الاكتئاب والتغييرات المزاجية والفكرية<br />مشاكل في القلب والأوعية الدموية<br />&bull; تغير ضغط الدم ونبضات القلب غير المنتظمة واتساع الأوعية الدموية<br />مشاكل في الرئة<br />&bull; الالتهاب الرئوي والتهاب الشعب الهوائية<br />&bull; ضيق التنفس والكحة<br />&bull; وجود مياه على الرئتين أو داخل الصدر<br />&bull; مشكلات في الجيوب الأنفية<br />مشاكل أخرى<br />&bull; فقدان الوزن وارتفاع نسبة السكر بالدم والنقرس</p><p>مشاكل غير معروفة (لا يمكن تقدير معدل التكرار من البيانات المتوفرة)<br />العدوى وعدوى الطفيليات<br />&bull; عدوى المخ<br />سيقوم الطبيب بإجراء اختبارات دم منتظمة للتعرف على أي تغييرات في:<br />&bull; عدد خلايا الدم<br />&bull; كمية السكر أو الدهون أو الكوليسترول الموجودة بالدم<br />قد يكون الأطفال أكثر عرضة من البالغين للإصابة ببعض الآثار الجانبية، ومنها: الإسهال<br />والعدوى وانخفاض عدد كرات الدم البيضاء والحمراء في الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن مرأى ومتناول أيدي الأطفال.<br />يجب عدم تخزين الدواء فوق ۳۰ درجة مئوية. يجب التخزين في العبوة الأصلية.<br />لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة. يشير تاريخ انتهاء<br />الصلاحية إلى آخر يوم من الشهر المذكور.<br />لا تستخدم أكسبت إذا لاحظت وجود أي علامات ظاهرة من التلف.<br />يجب عدم التخلص من الأدوية مع مياه المصرف الصحي أو النفايات المنزلية. اطلب من<br />الصيدلي معرفة كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد<br />في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعَالة هي مايكوفينوليت موفيتيل. يحتوي كل قرص مغلف على ٥۰۰ ملغم من<br />مايكوفينوليت موفيتيل.<br />المكونات الأخرى هي:<br />أساس القرص: مايكروكريستالين سيللوز، البوفيدون ، كروس كارميلوز الصوديوم، تلك،<br />وستيرات الماغنسيوم.<br />،(E ثاني أكسيد التيتانيوم ( 171 ،cps الطبقة المغلفة للقرص: هيبروميللوز 6<br />أنديجو كارمن بحيرة الألمونيوم ،(E ماكروجول ٤۰۰ ، أكسيد الحديد الأحمر( 172<br />.(E أكسيد الحديد الأسود ( 172 ،(E132)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أكسبت ٥۰۰ ملغم أقراص مغلفة عبارة عن أقراص مغلفة ذات لون أرجواني، كبسولة<br />&quot; و&quot; 500 ،&quot;AHI&quot; الشكل، محدبة من الجانبين، محفور على أحد جوانب القرص كلمة<br />على الجانب الاخر.<br />يتوفر أكسبت في شرائط وعبوات بأحجام مختلفة ( ٥۰ أو ۱٥۰ قرص لكل عبوة).<br />قد لا يتم طرح جميع الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل تصريح التسويق<br />شركة أكورد هيلثكير ليميتد<br />٤ إتش إف، ساج هاوس, ۳۱۹ بينر رود، نورث هارو، ميدلسيكس إتش أيه ۱<br />المملكة المتحدة</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة في 10/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accept 500mg film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains Mycophenolate Mofetil 500mg. For the full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. Accept 500mg film‐coated tablets are purple colored, capsule shaped, biconvex, film-coated tablets debossed 'AHI' on one side and '500' on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Mycophenolate Mofetil is indicated in combination with Cyclosporine and Corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Mycophenolate Mofetil should be initiated and maintained by appropriately qualified transplant specialists.</p><p>Use in renal transplant: Adults: Oral Mycophenolate Mofetil should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1g administered twice daily (2g daily dose). Children and adolescents (aged 2 to 18 years): The recommended dose of Mycophenolate Mofetil is 600mg/m2 administered orally twice daily (up to a maximum of 2g daily). Mycophenolate Mofetil should only be prescribed to patients with a body surface area greater than 1.5m2, at a dose of 1g twice daily (2g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction. Children (&lt; 2 years): There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</p><p>Use in cardiac transplant: Adults: Oral Mycophenolate Mofetil should be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5g administered twice daily (3g daily dose). Children: No data are available for paediatric cardiac transplant patients.</p><p>Use in hepatic transplant: Adults: Intravenous Mycophenolate Mofetil should be administered for the first 4 days following hepatic transplant, with oral Mycophenolate Mofetil initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5g administered twice daily (3g daily dose). Children: No data are available for paediatric hepatic transplant patients.</p><p>Use in elderly (&ge; 65 years): The recommended dose of 1g administered twice a day for renal transplant patients and 1.5g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly. Use in renal impairment: In renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt; 25ml/min/1.73m2), outside the immediate post-transplant period, doses greater than 1g administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p>Use in severe hepatic impairment No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.<br />Treatment during rejection episodes: MPA (Mycophenolic acid) is the active metabolite of Mycophenolate Mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Mycophenolate Mofetil is not required. There is no basis for Mycophenolate Mofetil dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection. Method of administration Accept 500mg film-coated tablets should be taken orally.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Mycophenolate Mofetil or to any of the excipients listed in section 6.1. Therefore, Mycophenolate Mofetil is contraindicated in patients with a hypersensitivity to Mycophenolate Mofetil or Mycophenolic acid or any of the excipients. Mycophenolate Mofetil is contraindicated in women who are breastfeeding (see section 4.6). For information on use in pregnancy and contraceptive requirements, see section 4.6.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients receiving immunosuppressive regimens involving combinations of medicinal product, including Mycophenolate Mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimize the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>Patients receiving Mycophenolate Mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.</p><p>Patients treated with immunosuppressants, including Mycophenolate Mofetil, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus associated nephropathy JC virus associated progressive multifocal leukoencephalopathy, PML ). Cases of hepatitis due to reactivation of hepatitis B or hepatitis C have been reported in carrier patients treated with immunosuppressants. These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.</p><p>Patients receiving Mycophenolate Mofetil should be monitored for neutropenia, which may be related to Mycophenolate Mofetil itself, concomitant medications, viral infections, or some combination of these causes. Patients taking Mycophenolate Mofetil should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt; 1.3 x 103/&mu;l), it may be appropriate to interrupt or discontinue Mycophenolate Mofetil.<br />Cases of pure red cell aplasia (PRCA) have been reported in patients treated with Mycophenolate Mofetil in combination with other immunosuppressants. The mechanism for Mycophenolate Mofetil-induced PRCA is unknown. PRCA may resolve with dose reduction or cessation of Mycophenolate Mofetil therapy. Changes to Mycophenolate Mofetil therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimize the risk of graft rejection (see section 4.8). Patients should be advised that during treatment with Mycophenolate Mofetil , vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5). Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</p><p>Because Mycophenolate Mofetil has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation, Mycophenolate Mofetil should be administered with caution in patients with active serious digestive system disease. Mycophenolate Mofetil is an IMPDH (Inosine Monophosphate Dehydrogenase) inhibitor. On theoretical grounds, therefore, it should be avoided in patients with rare hereditary deficiency of Hypoxanthine-Guanine Phosphoribosyl-Transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome. It is recommended that Mycophenolate Mofetil should not be administered concomitantly with Azathioprine because such concomitant administration has not been studied. In view of the significant reduction in the AUC of MPA by Cholestyramine, caution should be used in the concomitant administration of Mycophenolate Mofetil with medicinal products that interfere with enterohepatic recirculation because of the potential to reduce the efficacy of Mycophenolate Mofetil. The risk: benefit ratio of Mycophenolate Mofetil in combination with Tacrolimus or Sirolimus has not been established (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults. Aciclovir: Higher Aciclovir plasma concentrations were observed when Mycophenolate Mofetil was administered with Aciclovir in comparison to the administration of Aciclovir alone. The changes in MPAG (the phenolic glucoronide of MPA) pharmacokinetics (MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are Aciclovir concentrations, the potential exists for Mycophenolate Mofetil and Aciclovir, or its prodrugs, e.g. Valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur. Antacids and Proton Pump Inhibitors (PPIs): Decreased mycophenolic acid (MPA) exposure has been observed when antacids, such as Magnesium and Aluminium Hydroxides, and PPIs, including Lansoprazole and Pantoprazole, were administered with Mycophenolate Mofetil. When comparing rates of transplant rejection or rates of graft loss between Mycophenolate Mofetil patients taking PPIs vs. Mycophenolate Mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when Mycophenolate Mofetil was coadministered with Magnesium and Aluminium Hydroxides is considerably less than when Mycophenolate Mofetil was coadministered with PPIs. Cholestyramine: Following single dose administration of 1.5g of Mycophenolate Mofetil to normal healthy subjects pre-treated with 4g t.i.d of Cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2 ). Caution should be used during concomitant administration because of the potential to reduce efficacy of Mycophenolate Mofetil. Medicinal products that interfere with enterohepatic circulation: Caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of Mycophenolate Mofetil.</p><p>Cyclosporine A: Cyclosporine A (CsA) pharmacokinetics are unaffected by Mycophenolate Mofetil. In contrast, if concomitant Cyclosporine treatment is stopped, an increase in MPA AUC of around 30% should be expected.</p><p>Ganciclovir: Based on the results of a single dose administration study of recommended doses of oral Mycophenolate and Intravenous Ganciclovir and the known effects of renal impairment on the pharmacokinetics of Mycophenolate Mofetil (see section 4.2) and Ganciclovir, it is anticipated that coadministration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and Ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and Mycophenolate Mofetil dose adjustment is not required. In patients with renal impairment in which Mycophenolate Mofetil and Ganciclovir or its prodrugs, e.g. Valganciclovir, are coadministered, the dose recommendations for Ganciclovir should be observed and patients should be monitored carefully. Oral contraceptives: The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of Mycophenolate Mofetil (see section 5.2).</p><p>Rifampicin: In patients not also taking Cyclosporine, concomitant administration of Mycophenolate Mofetil and Rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%. It is recommended to monitor MPA exposure levels and to adjust Mycophenolate Mofetil doses accordingly to maintain clinical efficacy when Rifampicin is administered concomitantly. Sirolimus: In renal transplant patients, concomitant administration of Mycophenolate Mofetil and CsA resulted in reduced MPA exposures by 30-50% compared with patients receiving the combination of Sirolimus and similar doses of Mycophenolate Mofetil (see section 4.4). Sevelamer: Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when Mycophenolate Mofetil was concomitantly administered with Sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer Mycophenolate Mofetil at least one hour before or three hours after Sevelamer intake to minimize the impact on the absorption of MPA. There is no data on Mycophenolate Mofetil with phosphate binders other than Sevelamer. Trimethoprim/Sulfamethoxazole: No effect on the bioavailability of MPA was observed. Norfloxacin and Metronidazole: In healthy volunteers, no significant interaction was observed when Mycophenolate Mofetil was concomitantly administered with Norfloxacin and Metronidazole separately. However, Norfloxacin and Metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of Mycophenolate Mofetil.</p><p>Ciprofloxacin and Amoxicillin plus Clavulanic acid: Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral Ciprofloxacin or Amoxicillin plus Clavulanic acid. This effect tended to diminish with continued antibiotic use and to cease within a few days of their discontinuation. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of Mycophenolate Mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment. Tacrolimus: In hepatic transplant patients initiated on Mycophenolate Mofetil and Tacrolimus, the AUC and Cmax of MPA, the active metabolite of Mycophenolate Mofetil, were not significantly affected by coadministration with Tacrolimus. In contrast, there was an increase of approximately 20% in Tacrolimus AUC when multiple doses of Mycophenolate Mofetil (1.5g b.i.d) were administered to patients taking Tacrolimus. However, in renal transplant patients, Tacrolimus concentration did not appear to be altered by Mycophenolate Mofetil (see also section 4.4).</p><p>Other interactions: Coadministration of Probenecid with Mycophenolate Mofetil in monkeys raises plasma AUC of MPAG by 3-fold. Thus, other substance known to undergo renal tubular secretion may compete with MPAG and thereby raise plasma concentrations of MPAG or the other substance undergoing tubular secretion. Live vaccines: Live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: It is recommended that Mycophenolate Mofetil therapy should not be initiated until a negative pregnancy test has been obtained. Effective contraception must be used before beginning Mycophenolate Mofetil therapy, during therapy, and for six weeks following discontinuation of therapy (see section 4.5). Patients should be instructed to consult their physician immediately should pregnancy occur. The use of Mycophenolate Mofetil is not recommended during pregnancy and should be reserved for cases where no more suitable alternative treatment is available. Mycophenolate Mofetil should be used in pregnant women only if the potential benefit outweighs the potential risk to the foetus. There is limited data from the use of Mycophenolate Mofetil in pregnant women. However, congenital malformations including ear malformations i.e. abnormally formed or absent external/middle ear, have been reported in children of patients exposed to Mycophenolate Mofetil in combination with other immunosuppressants during pregnancy. Cases of spontaneous abortions have been reported in patients exposed to Mycophenolate Mofetil. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Lactation: Mycophenolate Mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to Mycophenolate Mofetil in breastfed infants, Mycophenolate Mofetil is contraindicated in nursing mothers (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic profile and the reported adverse reactions indicate that an effect is unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects cover adverse reactions from clinical trials: The principal adverse reactions associated with the administration of Mycophenolate Mofetil in combination with Cyclosporine and Corticosteroids include diarrhoea, leucopenia, sepsis and vomiting and there is evidence of a higher frequency of certain types of infections (see section 4.4).</p><p>Malignancies: Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Mycophenolate Mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving Mycophenolate Mofetil (2g or 3g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2g data), cardiac and hepatic transplant patients followed for at least 1 year. Non-Melanoma Skin Carcinomas occurred in 3.6% of patients; other types of malignancy occurred in 1.1% of patients. Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the one-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.</p><p>Opportunistic infections: All transplant patients are at increased risk of opportunistic infections; the risk increased with total immunosuppressive load (see section 4.4). The most common opportunistic infections in patients receiving Mycophenolate Mofetil (2g or 3g daily) with other immunosuppressants in controlled clinical trials of renal (2g data), cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, Cytomegalovirus (CMV) viraemia/syndrome and Herpes Simplex. The proportion of patients with CMV viraemia/syndrome was 13.5%.</p><p>Children and Adolescents (aged 2 to 18 years): The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600mg/m2 Mycophenolate Mofetil orally twice daily, were generally similar to those observed in adult patients given 1g Mycophenolate Mofetil twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopoenia, anaemia and infection.</p><p>Elderly patients (&ge; 65 years): Elderly patients (&ge;65 years) may generally be at increased risk of adverse reactions due to immunosuppression. Elderly patients receiving Mycophenolate Mofetil as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals. Other adverse reactions: Adverse reactions, probably or possibly related to Mycophenolate Mofetil, reported &ge; 1/10 and in &ge; 1/100 to &lt;1/10 of patients treated with Mycophenolate Mofetil in the controlled clinical trials of renal (2g data), cardiac and hepatic transplant patients are listed in the following table. Adverse reactions, probably or possibly related to Mycophenolate Mofetil, reported in patients treated with Mycophenolate Mofetil in renal, cardiac and hepatic clinical trials when used in combination with Cyclosporine and Corticosteroids.</p><p>Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (&ge;1/10) common (&ge;1/100 to &lt;1/10) uncommon (&ge;1/1,000 to &lt;1/100) rare (&ge;1/10,000 to &lt; 1/1,000) very rare (&lt; 1/10,000) not known (cannot be estimated from the available data) Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:682px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>System organ class </strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse drug reactions </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Skin cancer, benign neoplasm of skin</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Leucopenia, thrombocytopenia, anaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Pancytopenia, leucocytosis</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Tachycardia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Hypotension, hypertension, vasodilatation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Pleural effusion, dyspnoea, cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Vomiting, abdominal pain, diarrhoea, nausea</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Hepatitis, jaundice, hyperbilirubinaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="4" style="vertical-align:top"><p>Skin hypertrophy, rash, acne, alopecia,</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:682px"><tbody><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Oedema, pyrexia, chills, pain, malaise, asthenia,</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic enzyme increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, weight decreased</p></td></tr></tbody></table><p>Note: 501 (2g Mycophenolate Mofetil daily), 289 (3g Mycophenolate Mofetil daily) and 277 (2g IV / 3g oral Mycophenolate Mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively. The following undesirable effects cover adverse reactions from post-marketing experience: The types of adverse reactions reported during post-marketing with Mycophenolate Mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies. Additional adverse reactions reported during post-marketing are described below with frequencies reported within brackets if known. Gastrointestinal: Gingival hyperplasia (&ge;1/100 to &lt;1/10), Colitis including cytomegalovirus colitis, (&ge;1/100 to &lt;1/10), pancreatitis (&ge;1/100 to &lt;1/10) and intestinal villous atrophy. Disorders related to immunosuppression: Serious life threatening infections including meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Mycophenolate Mofetil. Agranulocytosis (&ge; 1/1000 to &lt;1/100) and neutropenia have been reported, therefore regular monitoring of patients taking Mycophenolate Mofetil is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow depression in patients treated with Mycophenolate Mofetil, some of which have been fatal.</p><p>Blood and lymphatic system disorder: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with Mycophenolate Mofetil (see section 4.4). Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with Mycophenolate Mofetil. These changes are not associated with impaired neutrophil function. These changes may suggest a &#39;left shift&#39; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive Mycophenolate Mofetil. Respiratory, thoracic and mediastinal disorders: There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with Mycophenolate Mofetil in combination with other immunosuppressants, some of which have been fatal. Hypersensitivity: Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction, have been reported. Congenital disorders: See further details in section 4.6.<br />Reporting of suspected adverse reactions<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with Mycophenolate Mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product. It is expected that an overdose of Mycophenolate Mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with Mycophenolate Mofetil should be interrupted or the dose reduced (see section 4.4). Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as Cholestyramine, can remove MPA by decreasing the enterohepatic recirculation of the drug (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressive agents ATC code: LO4AA06 Mechanism of Action: Mycophenolate Mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of Inosine Monophosphate Dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines whereas other cell types can utilize salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption Following oral administration, Mycophenolate Mofetil undergoes rapid and extensive absorption and complete pre-systemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of Mycophenolate Mofetil is correlated with MPA concentration. The mean bioavailability of oral Mycophenolate Mofetil, based on MPA AUC, is 94% relative to IV Mycophenolate Mofetil. Food had no effect on the extent of absorption (MPA AUC) of Mycophenolate Mofetil when administered at doses of 1.5g b.i.d to renal transplant patients. However, MPA Cmax was decreased by 40% in the presence of food. Mycophenolate Mofetil is not measurable systemically in plasma following oral administration.</p><p>Distribution As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the coadministration of Cholestyramine (4g t.i.d), indicating that there is a significant amount of enterohepatic recirculation. MPA at clinically relevant concentrations is 97% bound to plasma albumin.</p><p>Biotransformation MPA is metabolized principally by Glucuronyl Transferase to form the phenolic glucuronide of MPA (MPAG), which is not pharmacologically active.</p><p>Elimination A negligible amount of substance is excreted as MPA (&lt; 1% of dose) in the urine. Orally administered radiolabelled Mycophenolate Mofetil results in complete recovery of the administered dose; with 93% of the administered dose recovered in the urine and 6% recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis. However, at high MPAG plasma concentrations (&gt; 100&mu;g/ml), small amounts of MPAG are removed. In the early post-transplant period (&lt; 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 &ndash; 6 months post-transplant).</p><p>Renal impairment: In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt; 25ml/min/1.73m2) were 28 &ndash; 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. However, the mean single dose MPAG AUC was 3 &ndash; 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple dosing of Mycophenolate Mofetil in patients with severe chronic renal impairment has not been studied. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment. Delayed renal graft function: In patients with delayed renal graft function post-transplant, mean MPA AUC(0&ndash;12h) was comparable to that seen in post-transplant patients without delayed graft function. Mean plasma MPAG AUC(0-12h) was 2 &ndash; 3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. Dose adjustment of Mycophenolate Mofetil does not appear to be necessary.</p><p>Hepatic impairment: In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on this process probably depend on the particular disease. However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect. Children and adolescents (aged 2 to 18 years): Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients given 600mg/m2 Mycophenolate Mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving Mycophenolate Mofetil at a dose of 1g b.i.d in the early and late post-transplant period. MPA AUC values across age groups were similar in the early and late post-transplant period. Elderly patients (&ge; 65 years): Pharmacokinetic behaviour of Mycophenolate Mofetil in the elderly has not been formally evaluated. Oral contraceptives: The pharmacokinetics of oral contraceptives were unaffected by coadministration of Mycophenolate Mofetil (see section 4.5). A study of the coadministration of Mycophenolate Mofetil (1g b.i.d) and combined oral contraceptives containing Ethinylestradiol (0.02mg to 0.04mg) and Levonorgestrel (0.05mg to 0.15mg), Desogestrel (0.15mg) or Gestodene (0.05mg to 0.10mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of Mycophenolate Mofetil on the ovulation suppressing action of the oral contraceptives. Serum levels of LH, FSH and Progesterone were not significantly affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In experimental models, Mycophenolate Mofetil was not tumourigenic. The highest dose tested in the animal carcinogenicity studies resulted in approximately 2&ndash;3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2g/day and 1.3&ndash;2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3g/day.</p><p>Two genotoxicity assays (in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test) showed a potential of Mycophenolate Mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic mode of action, i.e. inhibition of nucleotide synthesis in sensitive cells. Other in vitro tests for detection of gene mutation did not demonstrate genotoxic activity. Mycophenolate Mofetil had no effect on fertility of male rats at oral doses up to 20mg/kg/day. The systemic exposure at this dose represents 2&ndash;3 times the clinical exposure at the recommended clinical dose of 2g/day in renal transplant patients and 1.3&ndash;2 times the clinical exposure at the recommended clinical dose of 3g/day in cardiac transplant patients.</p><p>In a female fertility and reproduction study conducted in rats, oral doses of 4.5mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.</p><p>In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3g/day for cardiac transplant patients (see section 4.6). The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with Mycophenolate Mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended doses. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The Non-clinical toxicity profile of Mycophenolate Mofetil appears to be consistent with adverse events observed in human clinical trials, which now provide safety data of more relevance to the patient population (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core tablet: Cellulose microcrystalline Povidone ( K-90 ) Hydroxypropylcellulose Croscarmellose sodium Talc Magnesium stearate<br />Coating:<br />Hypromellose 6 cps<br />Titanium dioxide (E171)<br />Macrogol 400<br />Iron oxide red (E172)<br />Indigo carmine aluminium lake (E132)<br />Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of sight and reach of children. Do not store above 30&deg;C. Store in the original pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Accept 500mg film-coated tablets are purple colored, capsule shaped, biconvex, film coated tablet debossed &#39;AHI&#39; on one side and &#39;500&#39; on other side. Accept is packed in blisters and is available in different pack sizes (50 or 150 tablets per pack). Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements. Because Mycophenolate Mofetil has demonstrated teratogenic effects in rats and rabbits, Accept 500mg film-coated tablets should not be crushed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2015 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>